Introduction

Symptomatic OA is generally defined by the presence of pain, aching, or stiffness in a joint with radiographic OA. The age-standardized prevalence of symptomatic hand and knee OA is 6.8% and 4.9%, respectively, in Framingham subjects age ≥26 years. However, prevalence of symptomatic knee OA was 16.7% among subjects age ≥45 in the Johnston County Osteoarthritis Project, much higher than that reported in the Framingham Study. About 9% of subjects in the Johnston County study had symptomatic hip OA [1].

Taking into account these percentages, there is no doubt on how important is to prevent or treat this pandemic pathology.

Classically, anti-inflammatory drugs where the pharmacologically option to treat OA, but during the last years new solutions have been founded and they seem encouraging. One of these solutions is the cartilage protector’s drugs that will be the subject of this manuscript.

A cartilage protector is a substance or chemical composite that delays OA progression and improves the joint function through the chondrocytes protection. They are included in a group called SYSADOAS (Symptomatic Slow Acting Drugs for Osteoarthritis) and are considered potentially as SDMOADs (Structure Disease Modifying Osteoarthritis Drugs).

Even if they don’t repair the existent damage, they seem to delay and reduce the OA progression between 3 and 6 months; and to determine if they can modified the illness progression a longer period of time in needed (no less than 2 years and probably more than 3 years) [2].

There are asymptomatic patients with radiological OA and patients with pain and normal x-rays [3-5].

There isn’t a correlation between clinical and radiological signs. The illness progression is variable; even if in the majority of cases in slow. Sometimes the symptoms improve with time and the radiological signs don’t progress [2,6].

Due to the doubts or the hope on this treatment for OA and the difficulty to demonstrate its clinical efficacy a validation of them with a clinical evidence analysis is needed.

Medicine Based Evidence presents a sceptical attitude through the diagnostic, prognostic and therapeutic techniques; allowing to take the better decision to resolve the problem. The way to complete this procedure consists on establish a relevant clinical question; perform a daily literature research; evaluate critically the quality of the studies, take decisions and apply correctly the obtained conclusions to the analyzed clinical problem.

Following this method, a positive or negative reason to use cartilage protection with oral chondroitin sulphate and glucosamine sulphate or hyaluronic acid intra articular has been searched. From the systemic revision performed till October 2014, the following studies were included: M with a randomized group control (ECA), systemic revision (RS) and meta analysis (MA); judging their design, performance and exposition. We have also critically review the revisions that accomplished the DARE criteria (Database of Abstracts of Reviews of Effects, Centre for Reviews and Dissemination, York University)

All the ECA, RS and MA included were reviewed even if on this review we have only included the most important to reduce the number of references. We have also used all the published letters directed to the authors and their letters in response. Their number is big and the show how interesting and controversial is this subject.

A quality and clinical evidence been assigned following the GRADE system (Grades of Recommendation, Assessment, Development and Evaluation) [7], the Oxford Centre for Evidence-Based Medicine scale [8] and the critical evaluation of Narvy and Vangsness [9].
All the studies considered low quality and the published before the year 2000 were excluded.

Classically, the effect size (TE) expressed as a standardized mean difference of a therapeutic action performed on a patients group is considered trivial when it is $< 0.20$; small if it is between 0.20 and 0.49; mild between 0.50 and 0.80; and big if it is $> 0.80$ [10]. To Dougados et al. a score lower than 0.20 is poor, between 0.20 and 0.40 is minimal, and from 0.40 till 0.60 moderate and more than 0.60 is clinically relevant on patients with chronic pain and knee OA [12].

The IMMPACT consensus says that, a TE of 0.20 is considered trivial when it is $< 0.20$; small if it is between 0.20 and 0.39; mild between 0.39 and 0.60; and big if it is $> 0.60$ [11].

The IMMPACT consensus says that, a TE of 0.20 is considered clinically relevant on patients with chronic pain and knee OA [12].

**Chondroitin Sulphate (CS)**

**Pharmacology**

It belongs to the glycosaminoglycan’s group, those are important structural components of the cartilage extracellular matrix organized in conglomerates of high molecular weight (proteoglycan) that represent approximately 50% of the hyaline cartilage. Proteoglycans contribute to determine the mechanical properties of the cartilage retaining water in the interior on the collagen matrix and allowing the characteristic answer to the charges loading. One step important on the arthritis process is the reduction of proteoglycans content on the cartilage submitting the collagen matrix to a bad mechanical function. The reduction of proteoglycans on the matrix it is due to the increase of the metalloproteinases activity: neutral, collagenases, gelatinases and estromelisine, allowed for the reduction of their specific inhibitors. CS action can be due to the stimulation of proteoglycan synthesis, hyaluronic acid and collagen type II and the specific inhibitors. CS action can be due to the stimulation of proteoglycan synthesis, hyaluronic acid and collagen type II and the reduction of the catabolic and anti-inflammatory activity; inhibiting inflammatory molecules as TNF-$\alpha$, IL-$1\beta$, COX-2, PGE2, NFkB; proteolytic enzymes like metalloproteinases 3, 9, 13 y 14, collagenase, elastase, phospholipase A2, catepsine B, aggrecanase 1 and 2; free radicals, nitric oxide and the chondrocyte apoptosis [13-17].

The use of CS in OA is justified on the results obtained on in vivo models that demonstrated that those exogenous sulphated glycosaminoglycans’ present a positive effect on the chondrocytes metabolism; stimulating the collagen type II, proteoglycans and hyaluronic acid production with a possible positive influence on a degenerative joint illness induced experimentally.

CS also helps on the subchondral bone remodeling increasing the expression and osteoprotegerin production and it reduces the RANKL (osteoclast differentiator) [18,19].

The dose employed on the majority of the clinical studies oscillates between 800 and 1200 mg per day, during a minimum period of 3 months [20-24].

In patients with knee OA the oral dose of 800 mg /day produces almost the same effect tan a dose of 1200 mg/day [25-26], and the treatment performed during three months two times a year obtains the same results as a continuous one [25].

10% of the fraction absorbed is CS and 90% substances with a lower molecular weight [17].

---

**Table 1: Systematic revision (RS) and meta-analysis (MA) of the use of chondroitin sulphate (CS) in patients with OA.**

| Author        | Year | Joint | Type study Level EC | Included studies | Heterogeneity $\phi$ | Results                           | Effect size TE (95% IC) | Conclusions               |
|---------------|------|-------|---------------------|------------------|---------------------|----------------------------------|-------------------------|--------------------------|
| McAlindon     | 2000 | Hip   | MA Level II         | 9 ECAs vs placebo | Significant         | Various                           | 0.06 (0.63-1.30)         | Low quality studies      |
| Richy         | 2003 | Knee  | MA Level II         | 8 ECAS vs placebo | Moderate            | Lequesne                         | 0.66 (0.64-1.09)         | Similar than SG          |
| Reichenbach   | 2007 | Knee  | MA Level II         | 20 ECAS/ECAs vs placebo or no treatment | High $\phi$ 92% | VAS Lequesne WOMAC | 0.75 (0.50-0.99) RR 0.98 (0.79-1.31) | Excellent inocuity |
| Monfort       | 2008 | Hip   | MA Level II         | 5 MAs vs placebo no treatment | High Significant | Pain Function Analgesics | Significant in 4 MAs and minimal 1 MA | Excellent inocuity |
| Hochberg      | 2010 | Knee  | MA Level I          | 4 ECAs vs placebo | No evidence $\phi$ 0 | Narrowing joint line | 0.23 (0.11-0.35) | Effective reducing narrowing joint line |
| Lee           | 2010 | Knee  | MA Level II         | 4 ECAs vs placebo | No evidence         | Narrowing joint line | 0.26 (0.13-0.39) | Delays ox OA progression |
| Wandel        | 2010 | Hip   | MA Level II         | 3 ECAs vs placebo | Heterogeneity low $\phi$ 0 | Narrowing joint line | 0.13 (0.00-0.37) | Compared to placebo it is not better |
| Schneider     | 2012 | Knee  | MA Level I          | 3 ECAs vs placebo | No evidence $\phi$ 0 | Lequesne | 0.73 (0.26-1.28) | Symptoms effective Treatment in knee OA K-L II-III |
| Gallagher     | 2014 | Knee  | RS Level II         | 4 ECAs vs placebo | Lequesne            | Reduces cartilage lost in 3 of 4 studies | 0.96 (0.63-1.30) | It can stop OA progression |

ECCAs: Studies with a control group nearly randomized; Heterogeneity: low $I^2$ = 25%; mild $I^2$ = 50%; high $I^2$ = 75%; RR: Relative Risk; K-L: Kellgren-Lawrence OA degrees; Rx: X-rays.

Citation: Fernández-Fairén MF and Torres A. Chondroprotection Validation. SM J Orthop. 2016; 2(2): 1034.
Table 2: Effect size on the joint line, meta-analysis of Hochberg et al. [Hochberg et al., 2010] from three randomised control studies where they employed the same CS during 2 years.

| Author Year          | Number of patients | Changes on the joint line | Mean ± standard deviation | Mean difference mm (95% IC) | Effect size (95% IC) |
|----------------------|--------------------|---------------------------|---------------------------|-----------------------------|----------------------|
| Michel et al. 2005   | 300                | –0.045±0.48               | 0.07±0.56                 | 0.12 (0.00-0.23)             | 0.22 (0.01-0.45)     |
| Sawitzke et al. 2008 | 257                | 0.107±0.68               | 0.166±0.68               | 0.06 (-0.17-0.28)           | 0.09 (-0.24-0.42)    |
| Kahan et al. 2009    | 622                | 0.07±0.03                | 0.31±0.04                 | 0.14 (0.06-0.21)            | 0.26 (0.11-0.42)     |
| Total                | 1179               | –                        | –                         | 0.13 (0.06-0.19)            | 0.23 (0.11-0.35)     |

*Standard error; IC: Confidence interval

After taking orally CS, the maximum blood concentration is achieved four hours later. Mean life of CS is 15 hours, the stationary period is reached in 3–4 days, the time needed to obtain the maximum effect is 35 days and at least from 4 to 6 months are needed to obtain the maximal effect [13,27].

Analyzing the content of CS on 11 nutrition supplements on the USA market a deviation between 10 and 110% were found; only 4 of them contained less than the 40% announced on their label. This was confirmed on a second analysis of 32 products [28].

With the CS sell at the chemist happens something similar [29].

Using CS non standardized can modified the result of some studies [30]. Pharmaceutic CS are regulated and standardized and present a high quality although the nutraceutical ones are poorer due to the lack of regulation existing on them [29].

The relative risk of adverse effects is 0.99 (95% IC 0.76-1.31) [31,32]. CS till a dose of 1200 mg/day is a treatment secure and non-toxic [33]. The clinical improvement produced after administrating 1200 mg in one dose one time per day is similar to that dose taken three times per day [26].

Effect on the clinical symptoms

During the two last decades multiple clinical studies said that CS improves the symptoms and function on patients with an effect that is continued during some months after the treatment [34].

Those studies results and those obtained on the MA concluded that CS is better than placebo on the reduction of pain, increase of functional capacity, reducing the amount of pain killers taken [35-37,23] and on the satisfaction of faculty and patient [23] (Table 1).

Even though, those MA show that CS has a efficacy from poor to mild on the symptomatic OA treatment with an excellent security profile [34,38,39,22,36,31].

The Pain on knee OA patient was positively controlled between the 6th and 8th week of treatment [40].

On the other hand, there are authors with high quality and methodological studies that have demonstrated a little effect on OA treatment; they suggest that the CS benefice on pain in minimal [31].

On the GAIT (Glucosamine/ Chondroitin Arthritis Intervention Trial) essay [20], 20 studies were analyzed showing more favorable results than the glucosamine (0.58; 95% IC 0.30-0.87), the NSAIDS (0.29; 95% IC 0.22-0.39) and the COX-2 inhibitors (0.44; 95% IC 0.28-0.63, 33-0.55) [31].

The result was statistically significant in 18 of them [31,41]. The methodology employed on this MA has been discussed [42,43].

Analyzing high quality studies of CS (Jadad 5) the effect size was not significant [32].

A symptomatic positive effect was seen in knee OA patients and also in patients with hand OA reducing pain and increasing function [44].

There were no differences seen in patients with low pain administrating CS, glucosamine, both, celecoxib and placebo [45,46].

The efficacy of CS reducing the symptoms is similar than SG, except for the detention of the OA progression that for CS was none [37].

Effects on the progression of OA

It has been studied if CS improved OA symptoms and stopped joint degeneration. After 2 years of treatment with CS the stabilization of the joint radiological line on knees was seen compared to the progression seen on the control group [39].

Patients with a joint narrow of the radiological line of less than 1 mm, didn’t experimented a radiological [22] or clinical [31] improvement.

In a MA [38] and a ECA [47] the mean effect of the studies was determined; the author concluded that the administration of 800 mg of CS per day during 2 year, in patient with knee OA, has a small effect but with a high statistical significant reducing the lack of joint line compared to placebo [38] (Table 2).

After two years of treatment a small protection joint effect was seen but significant (TE 0.26; 95% IC 0.22-0.39; p < 0.001) [48].

The results of this MA are contradictory with the ones obtained by Richy, et al [37].

Using the MRI in patients with knee OA, it has been demonstrated that after 6 months of treatment with 800 mg of CS per day reduces the loss of cartilage volume compared to placebo; and associated to a reduction of the damage of the subchondral bone. Those findings suggest a joint protector effect of CS [49,50].

Take home messages

CS is considered as a SYSADOA in Europe but in USA is considered as a nutritional supplement. In 2014, 16% of the population with OA in UK consumed CS [51,52].

To conclude

- CS is a natural substance that can be recommended as an action treatment with slow, secure and efficacy action in OA with possible delayed effect of the illness.

- CS can be used preferable in early periods of OA because its effect in advanced stages is lower or none [46,53,31].
Table 3: Glucosamine content per capsule on different commercial products [74].

| Product | Container (mg) | Glucosamine (mg) | Equivalent SG (mg) | % of the declared quantity |
|---------|---------------|------------------|--------------------|---------------------------|
| 1       | 500           | 409              | 519                | 82                        |
| 2       | 500           | 277              | 351                | 55                        |
| 3       | 500           | 325              | 445                | 65                        |
| 4       | 500           | 330              | 419                | 68                        |
| 5       | 500           | 248              | 315                | 50                        |
| 6       | 1500          | 634              | 804                | 42                        |
| 7       | 500           | 233              | 295                | 41                        |
| 8       | 500           | 298              | 378                | 60                        |
| 9       | 500           | 231              | 293                | 46                        |
| 10      | 500           | 274              | 348                | 55                        |
| 11      | 500           | 238              | 302                | 48                        |
| 12      | 500           | 169              | 214                | 56                        |
| 13      | 500           | 262              | 332                | 52                        |

- The pharmaceutic CS has a better quality that the nutraceutical ones [29].
- OARSI guide recommends the treatment with GS alone or combined with CS that can be symptomatic beneficial in patients with joint OA. If the patient doesn’t see an improvement after 6 months of treatment it needs to be stopped. Level Ia evidence [54]. The recommendation strength was 63% (95% IC 44-82%), being the NSAIDS 93% and paracetamol 92% (> 4 g/day) [54].
- CS has a level Ib of evidence on efficacy which sustains their use as a treatment in patients with hip OA. The strength of its recommendation based on it is efficacy is level A and it is based in all the evidence and clinical experience existent [55].
- EULAR recommends the use of CS in patients with knee OA, with an A recommendation degree; through a level evidence Ia [56].
- ESCEO (European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis) places CS in the first treatment step in patients with symptomatic knee OA [57].
- SER (Rheumatologist Spanish Society) recommends CS with an A degree to improve the symptoms in patients with knee OA (pain, function, reducing painkillers taken: level IA evidence) (radiological progression: level IB evidence) (reducing the number of patients that will need a TKR: no evidence).
- The evaluative agency of New Technologies Lain Entralgo (Madrid) places CS as a second line treatment for OA after the paracetamol and with a maximum degree of recommendation (IA) [58].
- Its favorable security profile, its good tolerance with different doses and after medium and long treatment and the lower frequency of adverse effects similar to placebo, makes CS an option to be taken into account, desirable and useful on OA treatment [30].

**Glucosamine Sulphate (SG)**

**Pharmacology**

Glucosamine (hexamine; C₆H₁₃NO₅) is a natural amino monosaccharide that constitutes part from some glycosaminoglycan’s like hyaluronic acid or keratin sulphate. It is placed on the hyaline cartilage extracellular matrix near the CS4 and the CS6, being the substrate to the cartilage proteoglycans biosynthesis; and can stimulate it [59]. It has an anti-inflammatory activity in OA, inhibiting mediators like the nitric oxide, the IL-1β, the ciclooxigenase-2, the metalloproteinasases, and some cartilage destructors enzymes like the collagenases, aggrecanases, phospholipases A2 and lysosomal enzymes and the formation of other substances like the peroxide macrophage radicals [60-63].

Glucosamine reduces bone resorption and combined with CS increases the expression of OPG/RANKL with a positive effect on the OA subchondral bone modifications [64].

It has been speculated if CS action can be due to its conversion on SG [60].

It is produced and used in Europe as a drug or as a nutraceutical in USA.

There were differences between studies were they have employed SG pharmaceutical versus the produced as a nutraceutical supplement.

The relative risk of adverse effects is 0.97 (95% IC 0, 08-1, 08) [65,32]. It is contraindicated in patients allergic to seafood. Diabetic patients had taken SG need to be carefully controlled because it can modify the glucose blood levels [66].

**Clinical symptoms effects**

The administration of glucosamine is more controversial than CS. A critical point is that it can be used as glucosamine sulphate or glucosamine hydrochloride (HCG), with important differences between them [67,68].

Actually HCG cannot be recommended regarding the clinical existing data [69]. Some authors have employed glucosamine intravenous and intramuscular [70,71], or intra articular [72,73].

Other important aspect is the difference on the active principle quantity existent between the different commercials products (Table 3) [74,67], some patients can be taking suboptimal doses [75,74].

The problem is that the minimal effective dose is not known and in humans taking 1500 mg per day the plasmatic concentrations reached by the glucosamine are lower than the experimental ones in vitro and in animals [75-77].

There is a MA where they show that SG taken during 12 weeks doesn’t reach the point of the minimal difference perception on patients with painful knee OA [40] (Table 4). The problem is that on the same analysis the authors concluded that paracetamol, SG and CS are efficient to achieve the pain reduction after 1 month of treatment. Only the NSAIDS orally or topic and corticosteroids present an effect compared to placebo after 1 month [40].

Two MA reported a moderate but significant result of the glucosamine on the symptoms [35], with a significant improvement on pain, mobility, Lequesne index and WOMAC [37].
SG one time a day during 3 years improve the symptoms in patients. Studies, Poolsup et al., concluded that the treatment with 1500 mg of medium follow-up (Table 5). Also through a MA of two high quality treatment improves the symptoms on the patient with knee OA at employed 1500 mg of SG per day [79-81], demonstrating that this statistically significant for the pain, the function and the stiffness on the function of 21% (Lequesne Index). Although, the results were not superior effect than placebo with pain improvement of 28% and on

\[
\text{WOMAC (TE pain -0.16; 95\% IC-0, 36-0, 0-4).}
\]

A Cochrane revision has confirmed that glucosamine has a superior effect than placebo with pain improvement of 28% and on the function of 21% (Lequesne Index). Although, the results were not statistically significant for the pain, the function and the stiffness on the WOMAC (TE pain -0.16; 95\% IC-0, 36-0, 0-4).

Glucosamine was as secure as placebo on the number of adverse effects [65].

There is a MA [78] with three high quality studies where they have employed 1500 mg of SG per day for more than 6 months. [78] from the three randomised studies where the same SG has been employed with a dose of 1500 mg one time per day for more than 6 months.

Table 4: Systematic revisions (RS) and meta-analysis (MA) on the use of glucosamine sulphate on patients with OA.

| Author | Study Type | Level | Included studies | Heterogeneity | Results | Effect size | Conclusions |
|--------|------------|-------|------------------|---------------|---------|-------------|-------------|
| McAlindon 2000 [35] | Hip Knee | MA Level II | 6 ECAs vs placebo | Significant | Various Pain line | 0.44 (0.24-0.64) | To exaggerate |
| Richy 2003 [37] | Knee | MA Level II | 7ECAs vs placebo | Moderate | Narrowing joint line | 0.41 (0.21-0.60) | Significant benefactions effects |
| Poolsup 2005 [82] | Knee | MA Level I | 2 ECAs vs placebo | No heterogeneity significant | Function Progression OA | 0.41 (0.21-0.60) | Long term efficacy on the improvement of symptoms and the detention of the OA progression |
| Reginster 2007 [78] | Knee | MA Level I | 3 ECAs vs placebo | No heterogeneity | WOMAC | 0.33 (0.17-0.49) | Small/medium effect but clinically acceptable |
| Vlad 2007 [67] | Hip Knee | MA Level II | 15 ECAs vs placebo | I² = 80\% | Pain | 0.44 (0.18-0.70) | Big heterogeneity |
| Towheed 2009 [65] | All joints except TM | MA Level II | 25 ECAs vs placebo 5 vs NSAIDs | I² = 92\% | Pain Lequesne Adverse effects | 0.47 (0.23-0.72) | Better than placebo on pain and function |
| Lee 2010 [84] | Knee | MA Level II | 2ECAs vs placebo | No evidence | Narrowing joint line | 0.43 (0.23-0.62) | It can delay OA progression |
| Wandel 2010 [86] | Hip Knee | MA Level II | 5ECAs vs placebo | Low heterogeneity | Pain Narrowing joint line | 0.17 (0.05-0.28) | Compared to placebo it doesn’t reduce pain and narrowing joint line |
| Wu 2013 [68] | Knee | MA Level I | 13 ECAs vs placebo | Pain I² = 82\% | Function progression, narrow joint line | 0.22 (<0.04-0.48) | No effect on pain after > 6 months it improves function |
| Gallagher 2014 [50] | Knee | RS Level II | 3 ECAs vs placebo | - | Narrowing joint line | 0.36 (0.17-0.56) | It can stop OA progression |

Table 5: Effect size on the change of the WOMAC values performed by Reginster [78] from the three randomised studies where the same SG has been employed with a dose of 1500 mg one time per day for more than 6 months.

SG controls better the symptoms than placebo and it is similar to acetaminophen [79].

The improvement persists between 6 months and 3 years suggesting a possible modification of the illness [80, 81].

Compared to NSAIDS, its action starts slowly between the 2nd and 3rd week but it has a better GI tolerance [83, 81, 82, 37,65]. The effect is maintained till 2 months after stopping the treatment [83].

The combined administration of glucosamine and GS has been studied. On the symptoms of patients with OA its effect is between moderate to big compare to placebo [20], with a 10% higher answer than the celecoxib [46]. The problem is that the quality of the different publications makes think that those effects can be exaggerated [35]. There is no evidence proving that the combination of both products offer any advantage than using just one of them [2] (Table 6).

Effect on the progression of OA

There are two studies showing a joint protect or effect of the SG after taking 1500 mg of SG per day during 3 months [80,81].

Different studies showed a reduction of the joint line narrowing [37,82,65]. A joint protector effect was seen employing SG (TE 0.43; 95\% IC 0, 23-0, 62; p < 0.001) [84,50].

After 8 years of follow-up 6.3\% patients with SG treatment were operated of a TKR compared to 14.5\% of the patients from the placebo group [57].

On the other hand, comparing the effects of glucosamine 500 mg three times per day, CS the combination of both, celecoxib and placebo during two years; no difference was seen on the delay of OA progression. Knees with a grade II Kellgren-Lawrence (K-L) treated

A Cochrane revision has confirmed that glucosamine has a superior effect than placebo with pain improvement of 28% and on the function of 21% (Lequesne Index). Although, the results were not statistically significant for the pain, the function and the stiffness on the WOMAC (TE pain -0.16; 95\% IC-0, 36-0, 0-4).

There is a MA [78] with three high quality studies where they have employed 1500 mg of SG per day [79-81], demonstrating that this treatment improves the symptoms on the patient with knee OA at medium follow-up (Table 5). Also through a MA of two high quality studies, Pools up et al., concluded that the treatment with 1500 mg of SG one time a day during 3 years improve the symptoms in patients with knee OA (95\% IC 0.21-0.60, 60) [82].

Table 5: Effect size on the change of the WOMAC values performed by Reginster [78] from the three randomised studies where the same SG has been employed with a dose of 1500 mg one time per day for more than 6 months.

| Author | Number of patients | Change on WOMAC score Mean ± standard deviation | Effect size* (95\% IC) |
|--------|-------------------|-----------------------------------------------|-----------------------|
| Reginster, et al. [78] | 212 | 229±347.5* 101±458.4* | 0.32 (0.04-0.59) |
| Paveika, et al. 2002 [80] | 202 | 8.0±8.7 4.9±8.2 | 0.37 (0.09-0.64) |
| Herreco-Beaumont, et al.† 2007 [79] | 210 | 12.9±14.1 8.2±16.0 | 0.31 (0.04-0.58) |
| Total | 624 | – | 0.33 (0.17-0.49) |

†estudio Glucosamine Unum In Die (once-a-day) Efficacy (GUIDE); IC: Confidence interval; *effect size > 0.00 favorable to glucosamine* WOMAC.

Citation: Fernández-Fairén MF and Torres A. Chondroprotection Validation. SM J Orthop. 2016; 2(2): 1034.
To conclude

Table 6: Different effects of the chondroprotectors in patients with knee OA, compared to placebo, from the analysis of Black, et al. [2].

| Product                        | Improvement in pain / function | Reducing painkillers intake | Narrowing of the joint line | Progression to TKR |
|--------------------------------|--------------------------------|-----------------------------|----------------------------|--------------------|
| Chondroitin sulphate           | Results heterogeneity          | Mixed evidence              | Efficacy evidence          | Non efficacy evidence |
| Glucosamine sulphate (SG)      | Efficacy evidence              | Non efficacy evidence       | Efficacy evidence          | Efficacy evidence   |
| Glucosamine hydrochloride (HCG)| Non efficacy evidence          | Non efficacy evidence       | Non efficacy evidence      | Non efficacy evidence |
| Glucosamine + chondroitin      | Results heterogeneity          | Efficacy evidence           | Non efficacy evidence      | Non efficacy evidence |

showed an improvement compared to placebo but this didn’t happen in patients with OA grade III.

The joint line narrowing was less when CS or GS was employed compared to the administration of both [47].

Pharmacokinetic studies reported lower glucosamine absorption when it is employed with CS [85].

There is a study where the authors said that GS and CS alone or combined presented a small benefit without clinical relevance on pain and narrowing of the joint line on hips and knees with OA [86]. But this study presents methodological mistakes [87,88].

After three years of treatment with SG the TKR incidence was reduced on a 57% during the following 5 years; this demonstrated that an effect size under 0.40 can be clinically significant [89].

SG has not showed effects on the symptoms and OA progression on patients with hip OA [90], the different results of GS on multiple joints, can be explained with the possibility of differences existent on the physiopathology of OA on different joints [91].

The administration of HCG doesn’t show structural benefits on chronic painful knees [92].

On the other hand, patients with knee OA, a mixed treatment of 1500 mg of SG and 800 mg of CS in one time a day dose compared to SG, CS or placebo after 2 years creating a significant reduction of the joint line compared to the other three groups [45].

To conclude

- OARSI guide in 2008 recommends the use of SG and CS in patients with symptomatic knee OA and can have structural effects modifications of the illness. Level Ia EC [54].
- EULAR says that there aren’t specific data of the use of SG as treatment in patients with hip OA. The recommendation strength evidence and clinical experience is 37.06 with a standard error recommendable [55].
- EULAR recommends the use of SG in patients with knee OA with an A degree of recommendation from an IA level of evidence and a TE between 0.43 and 1.02 [51].
- The Australian guide to the non-surgical hip and knee OA treatment recommends SG with a C recommendation degree [95].
- To the SER the treatment with SG has an A recommendation degree because it improves the symptoms in patients with knee OA (pain, function) and controls the radiological progression of a OA with a level 1a of evidence in both cases, with a level Ib of evidence to reduce the analgesic needs and without evidence to reduce the number of patients that will need a TRK.
- ESCEO (European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis) places the SG at the first step of treatment on patients with symptomatic knee OA [57].

Hyaluronic Acid (AH) Viscosupplementation

Hyaluronic acid is a non-sulphated glycosaminoglycan. It is the principal constituent of the synovial liquid with a concentration of 0.35 g/ml, and of a extracellular matrix layer of 1-2 μm thick at the cartilage surface. It works as a lubricant absorbing the loads and impacts. OA reduces the molecular AH weight. Its viscosity and its elastic module making them lost its mechanicals and rheological properties and increasing the vulnerability of the cartilage in front the loadings [96].

Pharmacology

Hyaluronic acid and sodium hyaluronate are known as hyaluronans. The hylan is a derivate of the AH, with multiple polymers. Those products are characterized with their molecular weight [97,98].

The AH native has a molecular weight of 4-10 MDa and the hylan 6-7 MDa. The products with a molecular weight between 0.5-1.5MDa can have an easy diffusion through the synovial interstitial matrix increasing its concentration and interacting with cells and reducing the inflammation [99].

In animal models, those products present a bigger efficacy than the ones with a molecular weight over 2.3MDa [100]. There is no evidence that this happens also in humans.
AH has an anabolic and anti-inflammatory activity and increases the production of AH endogenous, glycosaminoglycan's and tissue metalloproteinases inhibitors. It inhibits the production of PGE2, nitric oxide, free radicals, estromelisine, Il-1 and reduces the proliferation, migration and phagocytosis of the leukocytes and the apoptosis. The concentration increases after the injection of AH, maintaining the effects during 6 months [99].

The different products existent on the market are different on its composition, production method, dose, biological characteristics and possible clinical results [101,102].

They are normally administered intraarticular (IA) but there are also orally products [103]. If the treatment is effective it can be used after 6 months.

It has been commonly used on the knee.

The relative risk of local adverse effects is 1.49 (95% IC 1, 21-1, 83) [104,32], and for the AH with high molecular weight 2.04 (95% IC 1, 18-3, 53) [32] and they are mainly pain and inflammation.

Effect on the clinical symptoms

The AH has an analgesic and anti-inflammatory activity, reducing the symptoms of the OA. The short period effect of the AH is attributed to the normalization of the joint viscoelastic fluid. Long period effect of AH, is related to the restoration of the mobility, the decreasing of pain and the homeostasis rheological and metabolically of the joint. An important placebo effect has been also associated to the puncture-aspiration-injection manoeuvre [105].

On the Cochrane revision, the pain TE on the WOMAC scale oscillates between 1.22 (95% IC 0, 52-1, 93) favorable to the AH after 1-4 weeks of the injection and 1.04 (95% IC 0, 32-1, 75) after 14-26 weeks of injection. For the function the TE was 1.02 (95% IC 0, 42-1, 62) and 0.80 (95% IC 0, 24-1, 37) respectively [104].

The benefit of AH is time-variable. It doesn’t have an immediate effect. Compared to the corticosteroids intraarticular in patients with knee OA TE was –0.39 (95% IC –0, 65–0, 12) favorable to the corticosteroids after 2 weeks .4 weeks 0.01 (95% IC –0, 23–0, 21) and 8 weeks 0.22 (95% IC –0, 05–0, 49), similar to them at 12 weeks 0.35 (95% IC 0, 03–0, 66) and clearly better for the AH after 26 weeks 0.39 (95% IC 0, 18–0, 59) [106].

In aECA, there was a statistically difference between placebo and AH on reduction of pain, improvement of function, global satisfaction and the amount of painkillers taken [107].

In patients with knee OA, AH is efficacy after 4 weeks, TE de 0.31 (95% IC 0, 17-0, 45) reaches its peek after 8 weeks, TE de 0.46 (95% IC 0, 28-0, 65) and presents a residual effect detectable after 24 weeks, TE de 0.21 (95% IC 0, 10-0, 31) [108].

The action peak of the AH is bigger than the acetaminophen (0.14; 95% IC 0, 05-0, 23), NSAIDS (0.29; 95% IC 0, 22-0, 35) [108,32], and COX-2 inhibitors (0.44; 95% IC 0, 33–0, 55) [48]. The effect is maintained during some months [109-111].

AH has been employed in others joints like hip, ankle and painful shoulder.

Two low quality systematic revisions [112,96] and four ECAs [113-116] has studied the role of AH on hip OA. All the previous studies concluded that AH seems effective and secure.

There is a RS evaluating the effect of AH in ankle OA [117], they considered that AH can significantly improve the pain compared to saline fluid, exercise or arthroscopy

A RS [118], concluded that AH improves the pain but not the function and three ECAs [119-121] showing an improvement of pain and function without adverse effects but more studies are need to confirmed or not those conclusions.

The majority of those studies have been done in posttraumatic OA ankles not in primary OA ankles.

One ECA employed AH in OA shoulders. The study concluded that AH was clinically effective and well tolerated [122]. It has been also used in rizartrosis [123,101] and on temporo-mandibular OA [101].

There isn’t an evidence favorably to the AH and its molecular weight after 12 weeks of follow-up [124].

Some clinical essays performed with high molecular AH present more consistent results on improvement of pain and function [125,126] than hialuronate sodium.

No clinical difference has been founded between employing hylan against hylarone [116]. The absence of a bigger efficacious of the hylan compared to the hylarones and its higher risk of adverse effects has made some authors not recommended it [127]. But this is not clear because hylan only needs one injection per year, some studies said that its adverse effects are similar to hylarones and the improvement of the symptoms is maintained during 26 weeks [128,129].

The treatment with AH seems as effective as NSAIDS after 5 weeks of treatment [130] and as an injection of corticosteroids after 6 months [131], and more effective than NSAIDS after 9 months with economical-medical benefices and without an additional cost [39].

This efficacy is bigger in intermediate OA stages than in advances ones [132,133]. The patient’s age doesn’t influence on the therapeutic AH response [87].

A MA concluded that AH has an innocuity similar than saline serum [134] and significantly greater than NSAIDS [130].

Effect on the OA progression

There is a study of Wang et al showing a favorable effect of AH on the cartilage volume lost [135]. There is where the authors said that more studies are needed to establish some conclusions [50].
To conclude on knee OA.

The viscosupplementation is approved by the FDA to be employed on knee OA.

**References**

1. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, Gabriel S. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008; 58: 26-35.
2. Black C, Clar C, Henderson R, MacEachem C, McNamane P, Quayyum Z, et al. The clinical effectiveness of glucosamine and chondroitin supplements in slowing or arresting progression of osteoarthritis of the knee: a systematic review and economic evaluation. Health Technol Assess. 2009; 13: 1-148.
3. Fautrel B, Hilliquin P, Rozenberg S, Allaert FA, Coste P, Leclerc A, et al. Impact of osteoarthritis: results of a nationwide survey of 10,000 patients consulting for OA. Joint Bone Spine. 2005; 72: 235-240.
4. Garstang SV, Stittik TP. Osteoarthritis: epidemiology, risk factors, and pathophysiology. Am J Phys Med Rehabil. 2006; 85: S2-11.
5. Sowers M. Epidemiology of risk factors for osteoarthritis: systemic factors. Curr Opin Rheumatol. 2001; 13: 447-451.
6. National Collaborating Centre for Chronic Conditions. Osteoarthritis: national clinical guideline for care and management in adults. London: Royal College of Physicians. 2008. Nivel II de EC.
7. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH. Grading quality of evidence and strength of recommendations. BMJ. 2004; 328: 1490.
8. Levels of Evidence. Oxford Centre for Evidence-based Medicine. 2011
9. Nary SJ, Vangscott CT. Critical appraisal of the role of glucosamine and chondroitin in the management of osteoarthritis of the knee. Nut Diet Suppl. 2012; 2: 13-25.
10. Parker RI, Hagan-Burke S. Useful effect size interpretations for single case research. Behav Ther. 2007; 38: 95-105.
11. Dougados M. Initiation du clinicien au langage statistique et méthodologique. En: La mesure. Paris: Expression Scientifique Publication. 1996.
12. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008; 9: 105-121.
13. du Souich P, Verges J. Simple approach to predict the maximal effect elicited by a drug when plasma concentrations are not available or are dissociated from the effect, as illustrated with chondroitin sulfate data. Clin Pharmacol Ther. 2001; 70: 5-9.
14. Henrotin Y, Mattly M, Sanchez C, Lambert C. Chondroitin sulfate in the treatment of osteoarthritis: from in vitro studies to clinical recommendations. Musculoskelet Dis. 2010; 2: 335-348.
15. Jomphe C, Gabriac M, Hale TM, Héroux L, Trudeau LE, Deblois D, et al. Chondroitin sulfate inhibits the nuclear translocation of nuclear factor-kappaB in interleukin-1beta-stimulated chondrocytes. Basic Clin Pharmacol Toxicol. 2008; 102: 59-65.
16. Maneiro E, Fernández Sueiro JL, Lema B, De Toro FJ, Gaido F, Blanco FJ. Efecto del condroitín sulfato sobre la producción de óxido nítrico por los condroctitos humanos artroscópicos. RevEspReumatol. 2001; 28: 12-17.
17. Monfort J, Pelletier JP, Garcia-Giralt N, Martel-Pelletier J. Biochemical basis of the effect of condroitin sulphate on osteoarthritides articular tissues. Ann Rheum Dis. 2008; 67: 735-740.
18. du Souich P, García AG, Vergés J, Montell E. Immunomodulatory and anti-inflammatory effects of chondroitin sulphate. J Cell Mol Med. 2009; 13: 1451-1463.
19. Tat SK, Pelletier JP, Lajunenese D, Fahmi H, Lavigne M, Martel-Pelletier J. The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells. ClinExpReumatol. 2008; 26: 295-304.
20. Clegg DO, Reda DJ, Haire RL, Klein MA, O’Dell JR, Hooper MM, et al.
Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006; 354:795-808.

21. Mazières B, Hucher M, Zaim M, Gamero P. Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2007; 66: 639-645.

22. Michel BA, Stucki G, Frey D, De Valthaire F, Vignon E, Bruehmann P, Uebelhart D. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum. 2005; 52: 779-786.

23. Uebelhart D, Malaise M, Marcolongo R, Piperno M, Mailleux E, Fioravanti A, et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cartilage. 2004; 12: 269-276.

24. Verbruggen G, Goemaere S, Veys EM. Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Clin Rheumatol. 2002; 21: 231-243.

25. Uebelhart D. Clinical review of chondroitin sulfate in osteoarthritis. Osteoarthritis Cartilage. 2008; 16: S19-21.

26. Zegels B, Crozes P, Uebelhart D, Bruyère O, Reginster JY. Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study. Osteoarthritis Cartilage. 2013; 21: 22-37.

27. Uebelhart D, Thonar EJ, Delmas PD, Chantreline A, Vignon E. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage. 1996; 6: 39-46.

28. Adebowaile A, Cox DS, Liang Z, Edington ND. Analysis of glucosamine and chondroitin sulfate content in marketed products and the Caco-2 permeability of chondroitin sulfate raw materials. Am Nutraceutical Assoc. 2000; 3: 37-44.

29. Volgi N. Quality of different chondroitin sulfate preparations in relation to their therapeutic activity. J Pharm Pharmacol. 2009; 61: 1271-1280.

30. Rainsford KD. Importance of pharmaceutical composition and evidence from clinical trials and pharmacological studies in determining effectiveness of chondroitin sulphate and other glycosamionglycans: a critique. J Pharm Pharmacol. 2009; 61: 1263-1270.

31. Reichenbach S, Sturchi R, Scherer M, Trelle S, Bürgi E, Bürgi U, et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. below Ann Intern Med. 2007; 146: 580-590.

32. Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, Biema-Zeinstra S. OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage. 2010; 18: 476-499.

33. Hathcock JN, Shao A. Risk assessment for glucosamine and chondroitin sulfate. Regul Toxicol Pharmacol. 2007; 47: 78-83.

34. Bana G, Jamard B, Verrouil E, Mazières B. Chondroitin sulfate in the management of hip and knee osteoarthritis: an overview. Adv Pharmacol. 2006; 53: 507-522.

35. McNilin TD, LaValley MP, Gulin JP, Felson DT, Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA. 2000; 283: 1469-1475.

36. Monfort J, Martel-Pelletier J, Pelletier JP. Chondroitin sulfate for symptomatic osteoarthritis: critical appraisal of meta-analyses. Curr Med Res Opin. 2008; 24: 1303-1308.

37. Richy F, Bruyere O, Ethgen O, Cucherat M, Henriot Y, Register JY. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med. 2003; 163: 1514-1522.

38. Hochberg MC. Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration. Osteoarthritis Cartilage. 2010; 18: 528-31.

39. Kahan A, Uebelhart D, De Valthaire F, Delmas PD, Register JY. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2009; 60: 524-533.

40. Bjorndal JM, Klovning A, Ljunggren AE, Sandler L. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: A meta-analysis of randomised placebo-controlled trials. i Eur J Pain. 2007; 11: 125-138.

41. Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews (2007b). Meta-analysis: chondroitin for osteoarthritis of the knee or hip.

42. Goldberg H, Avins A. Interpretation of chondroitin meta-analysis. Rapid Responses for Reichenbach et al. Ann Intern Med. 2007; 146: 580-590.

43. duSouich. Clinical usefulness of chondroitin sulfate. Rapid Responses for Reichenbach et al. Ann Intern Med. 2007; 146: 580-590.

44. Gabay C, Medinger-Sadowski C, Gascon D, Kolo F, Finch A. Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial at a single center. Arthritis Rheum. 2011; 63: 3383-3391.

45. Fransen M, Agaliotis M, Naim L, Votrubec M, Bridgett L, Su S, et al. on behalf of the LEMS study collaborative group [Epub ahead of print]. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis. 2014.

46. Hochberg MC, Ciegg DO. Potential effects of chondroitin sulfate on joint swelling: a GAIT report. Osteoarthritis Cartilage. 2008; 16: S22-24.

47. Sawitzke AD, Shi H, Finco MF, Dunlop DD, Bingham CO 3rd, Harris CL, et al. The effect of glucosamine and/or chondroitin sulf on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial. Arthritis Rheum. 2008; 58: 3183-3191.

48. Lee C, Hunsche E, Balshaw R, Kong SX, Schnitzer TJ. Need for common internal controls when assessing the relative efficacy of pharmacologic agents using a meta-analytic approach: case study of cyclooxygenase 2-selective inhibitors for the treatment of osteoarthritis. Arthritis Rheum. 2005; 53: 510-518.

49. Wild LM, Raynauld JP, Martel-Pelletier J, Beaulieu A, Bessette L, Morin F, Abram F, et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis. 2011; 70: 982-989.

50. Gallagher B, Tjomakaris FP, Harwood MI, Good RP, Ciccoitti MG, Freedman KB. Chondroprotection and the prevention of osteoarthritis progression of the knee: a systematic review of treatment agents. in Am J Sports Med. 2015; 43: 734-744.

51. Jordan KM, Sawyer S, Coakley P, Smith HE, Cooper C, Arden NK. The use of conventional and complementary treatments for knee osteoarthritis in the community. Rheumatology (Oxford). 2004; 43: 381-384.

52. Rubio-Terrés C, Grupo del estudio VECTRA. [An economic evaluation of chondroitin sulfate and non-steroidal anti-inflammatory drugs for the treatment of osteoarthritis. Data from the VECTRA study]. Reumatol Clin. 2010; 6: 187-195.

53. Lazenbek LB, Drozduv VN. [Efficacy of chondroitin sulfate in the treatment of elderly patients with gonarthrosis and coxarthrosis]. Ter Arkh. 2005; 77: 64-69.

54. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altaman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartil. 2008; 16: 137-162.

55. Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for...
International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2005; 64: 669-681.

56. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Diepepe P, et al. Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT. EULAR Recommendations 2003: an evidence-based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003; 62:1145-1155.

57. Bruyère O, Cooper C, Pelletier JP, Branco J, Brandi ML, Guillemin F, et al. [Epub ahead of print]. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Osteoarthr Cartilage. 2014.

58. Gracia San Román FJ, Calcerrada Díaz Santos N. Grupo de trabajo de la guía clínica de práctica del manejo del paciente con artritis de rodilla en atención primaria Madrid: Unidad de Evaluación de Tecnologías Sanitarias (UETS), Área de Investigación y Estudios Sanitarios. Agencia Lain Enralgo. 2006.

59. Bassleer C, Rovati L, Franchimont P. Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritic articular cartilage in vitro. Osteoarthr Cartilage. 1998; 6: 427-434.

60. Aghazadeh-Habashi A, Sattari S, Pasutto F, Jamal F. Single dose pharmacokinetics and bioavailability of glucosamine in the rat. J Pharm Pharm Sci. 2002; 5: 181-184.

61. Calamia V, Ruiz-Romero C, Rocha B, Fernández-Puente P, Mateos J, Montell E, et al. Pharmacoproteomic study of the effects of chondroitin and glucosamine sulfate on human articular chondrocytes. Arthritis Res Ther. 2010; 12: R138.

62. Nakamura H, Shibakawa A, Tanaka M, Kato T, Nishioka K. Effects of glucosamine hydrochloride on the production of prostaglandin E2, nitric oxide and metalloproteinases by chondrocytes and synoviocytes in osteoarthritis. Clin Exp Rheumatol. 2004; 22: 293-299.

63. Raffi MM, Yadav PN, Rossi AO. Glucosamine inhibits LPS-induced COX-2 and iNOS expression in mouse macrophage cells (RAW 264.7) by inhibition of p38-MAP kinase and transcription factor NF-kappaB. J Mol Nutr Food Res. 2007; 51: 587-593.

64. Tat SK1, Pelletier JP, Vergés J, Lajeunesse D, Montell E, Fahmi H, Lavigne J. Efficacies of different preparations of glucosamine for the treatment of osteoarthritis. Lancet.2001; 357:1618-9.

65. Chan NN, Baldeweg SE, Tan TMM, Hurel SJ. Glucosamine sulphate and intra-articular hyaluronic acid for treatment of osteoarthritis in the elderly. Curr Pharm Des. 2010; 16: 631-640.

66. Pavelká K, Gatterová J, Olejarová M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulphate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2002; 162: 2113-2123.

67. Reginster JY, Deroisy R, Provot F, Tardivel C, Pichard A, Deroisy R, et al. The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate on the osteoarthritis progression: a meta-analysis. Osteoarthr Cartilage. 2010; 18: 297-302.

68. Abad Santos F, Ochoa D, García AG. Actualización de la eficacia de condroitín sulfato y sulfato de glucosamina en el tratamiento de la artritis. AFT. 2011; 9: 97-108.

69. Lee YH, Woo JH, Choi SJ, Ji JD, Song GG. Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. Rheumatol Int. 2010; 30: 357-363.

70. Jackson CG, Plaas AH, Sandy JD, Hua C, Kim-Rolands S, Barnhill JG, et al. The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination. Osteoarthritis Cartilage. 2010; 18: 293-299.

71. Herrero-Beaumont G, Iovra JA, Del Carmen Trabado M, Blanco FJ, Benito P, Martín-Mola E, et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum. 2007; 56: 555-567.

72. Block JA, Oegera TR, Sandy JD, Plaas A. The effects of oral glucosamine on joint health: is a change in research approach needed? Osteoarthr Cartilage. 2010; 18: 5-11.

73. Reginster JY. The efficacy of glucosamine sulphate in osteoarthritis: financial and nonfinancial cost of interest. Arthritis Rheum. 2007; 56: 2105-2110.

74. Herrero-Beaumont G, Jurin JA, Del Carmen Trabado M, Blanco FJ, Benito P, Martín-Mola E, et al. Glucosamine sulphate in the treatment of knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthritis Cartilage. 2008; 16: 297-302.

75. Wandel S, Jüni P, Tendal B, Nüesch E, Villiger PM, Welton NJ, et al. Effects of glucosamine, chondroitin and/or knee: network meta-analysis. BMJ. 2010; 341: c4675.

76. Herrero-Beaumont G, Jurin JA, Del Carmen Trabado M, Blanco FJ, Benito P, Martín-Mola E, et al. Glucosamine sulphate in the treatment of knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthritis Cartilage. 2008; 16: 257-265.
108. Lo GH, LaValley M, McAlindon T, Felson DT. Intra-articular hyaluronic acid injection for knee osteoarthritis: a meta-analysis. JAMA. 2003; 290: 3115-8123.

109. van den Bekerom MP, Lamme B, Sermon A, Mulier M. What is the evidence for vicosupplementation in the treatment of patients with hip osteoarthritis? Systematic review of the literature. Arch Orthop Trauma Surg. 2008; 128: 815-823.

110. van der Linden S, Smits M, van Rijswijk MH, van Leeuwen B. The biological action of hyaluronan on human osteoarthritic articular chondrocytes: the importance of molecular weight. ClinExpRheumatol. 2004; 22: 307-312.

111. Bagga H, Burkhart D, Sambrook P, March L. Long-term effects of intraarticular hyaluronic acid on synovial fluid in osteoarthritis of the knee. J Rheumatol. 2006; 33: 946-950.

112. Ghosh P, Guidolin D. Potential mechanism of action of intra-articular hyaluronic acid treatment in osteoarthritis: are the effects molecular weight dependent? J Rheumatol. 2002; 32: 10-37.

113. Migliore A, Giovannangeli F, Granata M, Laganà B. Hylan g-f 20: review of the literature. Arthritis Care Res. 2009; 23: 87-92.

114. Sakulbumrungsil R. Comparative efficacy of low- and high-molecular weight hyaluronic acid (Hyaluritrix) injections versus local anesthetic in osteoarthritis of the hip. Arthritis Rheum. 2006; 50: 824-830.

115. Tzik C, Unli Z, Sener A, Efe M, Tüzün C. Comparison of the efficacy of lower and higher molecular weight viscosupplementation in the treatment of hip osteoarthritis. S Clin Rheumatol. 2005; 24: 244-250.

116. Shank BV, Hsiao MY, Chen WS, Wang TG, Chien KL. Effectiveness of intra-articular hyaluronic acid for ankle osteoarthritis treatment: a systematic review and meta-analysis. Arch Phys Med Rehabil. 2013; 94: 951-60.

117. Martin CW, WorkSafeBC Evidence-Based Practice Group. The efficacy/ effectiveness of vicosupplementation in treating ankle, including talocalcaneal joint, osteoarthritis of primary or secondary origin: A rapid review. Vancouver (BC): WorkSafeBC. 2009.

118. Amsterdam J, Vingerling JR, van Dijk J, Scholten PM, Roos EM, Bouter LM. A systematic review of the evidence base of glucosamine for osteoarthritis of the knee and hip. Osteoarthritis Cartilage. 2003; 11: 667-677.

119. Heyworth BE, Lee JH, Kim PD, Lipton CB, Strauch RJ, Rosenwasser MP. Hylan versus corticosteroid versus placebo for treatment of basal joint arthritis: a prospective, randomized, double-blind clinical trial. J Hand Surg Am. 2008; 33: 40-48.

120. Bongkotphet K, Tassanawipas W, Krittinayunt S, Songpatanasilp T, Bongkotphet K, Tassanawipas W, Krittinayunt S, Songpatanasilp T. Comparison of the efficacy of low- and high-molecular weight intra-articular hyaluronic acid in patients with knee osteoarthritis. J Health Res. 2009; 23: 87-92.

121. Aggarwal A, Sempowski IP. Hyaluronic acid injections for knee osteoarthritis. Systematic review of the literature. Can Fam Physician. 2004; 50: 249-256.
126. Berenbaum F, Grifka J, Cazzaniga S, D’Amato M, Giacovelli G, Chevalier X, et al. A randomised, double-blind, controlled trial comparing two intra-articular hyaluronic acid preparations differing by their molecular weight in symptomatic knee osteoarthritis. Ann Rheum Dis. 2012; 71: 1454-1460.

127. Reichenbach S, Blank S, Rutjes AW, Shang A, King EA, Dieppe PA, et al. Hylan versus hyaluronan for osteoarthritis of the knee: a systematic review and meta-analysis. Arthritis Rheum. 2007; 57: 1410-1418. Nivel I de EC.

128. Adams ME, Lussier AJ, Peyron JG. A risk-benefit assessment of injections of hyaluronan and its derivatives in the treatment of osteoarthritis of the knee. Drug Saf. 2000; 23: 115-130.

129. Strand V, Baraf HS, Lavin PT, Lim S, Hosokawa H. Effectiveness and Safety of a Multicenter Extension and Retreatment Trial of Gel-200 in Patients with Knee Osteoarthritis. Cartilage. 2012; 3: 297-304.

130. Ishijima M, Nakamura T, Shimizu K, Hayashi K, Kikuchi H, Soen S, et al. and for the Research Group of Cartilage Metabolism. Intra-articular hyaluronic acid injection versus oral non-steroidal anti-inflammatory drug for the treatment of knee osteoarthritis: a multi-center, randomized, open-label, non-inferiority trial Arthritis Res Ther. 2014; 16: R18.

131. Leopold SS, Redd BB, Warne WJ, Wehrle PA, Pettis PD, Shott S. Corticosteroid compared with hyaluronic acid injections for the treatment of osteoarthritis of the knee. A prospective, randomized trial. J Bone Joint Surg Am. 2003; 85-B: 1197-203.

132. Brzusek D, Petron D. Treating knee osteoarthritis with intra-articular hyaluronans. Curr Med Res Opin. 2008; 24: 3307-3322.

133. Dagenais S. Intra-articular hyaluronic acid (viscosupplementation) for knee osteoarthritis. Issues Emerg Health Technol. 2006; 1-4.

134. Miller LE, Block JE US-approved intra-articular hyaluronic acid injections are safe and effective in patients with knee osteoarthritis: systematic review and meta-analysis of randomized, saline-controlled trials. Clin Med Insights Arthritis MusculoskeletDisord. 2013; 6: 57-63.

135. Wang CT, Lin J, Chang CJ, Lin YT, Hou SM. Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. A meta-analysis of randomized controlled trials. J Bone Joint Surg Am. 2004; 86-A: 538-545.

136. Jacobs N, Kane T, Clarke H. Cost of outpatient viscosupplementation. Br J Health Care Manag. 2008; 14: 535-538.

137. Arnold W1, Fullerton DS, Holder S, May CS. Viscosupplementation: managed care issues for osteoarthritis of the knee. J Manag Care Pharm. 2007; 13: S3-19.

138. Elliott RA1, Hooper L, Payne K, Brown TJ, Roberts C, Symmons D. Preventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective in the general population? Rheumatology (Oxford). 2006; 45: 606-613.

139. Chou CW1, Lue KH, Lee HS, Lin RC, Lu KH. Hylan G-F 20 has better pain relief and cost-effectiveness than sodium hyaluronate in treating early osteoarthritic knees in Taiwan. J Formos Med Assoc. 2009; 108: 663-672.

140. Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews. HylanG-F 20 has better pain relief and cost-effectiveness than sodium hyaluronate in treating early osteoarthritic knees in Taiwan. 2005b.

141. Samson DJ, Grant MD, Ratko TA, Bonnell CJ, Ziegler KM, Aronson N. Treatment of Primary and Secondary Osteoarthritis of the Knee. Evidence Report/Technology Assessment No. 157 (Prepared by Blue Cross and Blue Shield Association Technology Evaluation Center Evidence based Practice Center under Contract No. 290-02-0028). AHRQ Publication No. 07-07320. Rockville, MD: Agency for Healthcare Research and Quality. September. 2007.

142. CajigasMelgoza JC, ArizaAndraca R, Espinosa Morales R, Méndez Medina C, Mirassou Ortega M, Robles San Román M. Guía de práctica clínica basada en la evidencia para el diagnóstico y tratamiento de la osteoartritis. MedIntMex. 2011; 27: 552-572.

143. Espinosa Morales R, Arce Salinas CA, CajigasMelgoza JC, Esquivel Valerio JA, Gutiérrez Gómez JJ, Martínez Hernández JL, et al. Reunión multidisciplinaria de expertos en diagnóstico y tratamiento de pacientes con osteoartritis. Actualización basada en evidencias. Med Int Mex. 2013; 29: 67-92.

144. Dougados M. Symptomatic slow-acting drugs for osteoarthritis: what are the facts? Joint Bone Spine. 2006; 73: 606-609.

145. Zhang W, Doherty M. EULAR recommendations for knee and hip osteoarthritis: a critique of the methodology. Br J Sports Med. 2006; 40: 664-669.

146. Porcheret M, Jordan K, Croft P. Primary Care Rheumatology Society. Treatment of knee pain in older adults in primary care: development of an evidence-based model of care. Rheumatology (Oxford). 2007; 46: 638-648.

147. Henrotin Y, Marty M, Mobasheri A. What is the current status of chondroitin sulfate and glucosamine for the treatment of knee osteoarthritis? Maturitas. 2014; 78: 184-187.

148. Schneider H, Maheu E, Cucheral M. Symptom-modifying effect of chondroitin sulfate in knee osteoarthritis: A meta-analysis of randomized placebo-controlled trials performed with Structum. Open Rheumatol J. 2012; 6: 183-189.

149. Byrne MM, O’Malley K, Suarez-Almazor ME. Willingness to pay per quality-adjusted life year in a study of knee osteoarthritis. Med Decis Making. 2005; 25: 655-666.

150. Segal L, Day SE, Chapman AB, Osborne RH. Can we reduce disease burden from osteoarthritis? Med J Aust. 2004; 180: S11-S7.

151. Torrance GW, Raynauld JP, Walker V, Goldsmith CH, Bellamy N, Band PA, et al. Canadian Knee OA Study Group. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hyalan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic results. Osteoarthritis Cartilage. 2002; 10: 518-527.